These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18823843)

  • 1. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.
    Venero CV; Thompson PD; Fernandez AB
    Am J Med; 2008 Oct; 121(10):e3-4. PubMed ID: 18823843
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
    Magee G; Sharpe PC
    J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
    Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
    Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
    Keidar S; Guttmann H; Stam T; Fishman I; Shapira C
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
    Unnikrishnan R; Das R; Jaydip R; Sudhakaran C; Mohan V
    J Assoc Physicians India; 2009 Feb; 57():180-1. PubMed ID: 19582991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
    Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
    Karalliedde J; Viberti GC
    Diabetes; 2007 May; 56(5):e3; author reply e4. PubMed ID: 17470560
    [No Abstract]   [Full Text] [Related]  

  • 9. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.
    Ebcioglu Z; Morgan J; Carey C; Capuzzi D
    Ann Intern Med; 2003 Nov; 139(9):W80. PubMed ID: 14597479
    [No Abstract]   [Full Text] [Related]  

  • 11. Fenofibrate-induced myopathy.
    Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
    Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iatrogenic severe depression of high-density lipoprotein cholesterol.
    Mymin D; Dembinski T; Friesen MH
    J Clin Pharmacol; 2009 Jul; 49(7):865-71. PubMed ID: 19403838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
    Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].
    Gariot P; Pointel JP; Barrat E; Drouin P; Debry G
    Biomed Pharmacother; 1984; 38(2):101-6. PubMed ID: 6743770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate-induced photosensitivity.
    Leenutaphong V; Manuskiatti W
    J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):775-7. PubMed ID: 8912578
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug safety. Heart attack risk overshadows a popular diabetes therapy.
    Couzin J
    Science; 2007 Jun; 316(5831):1550-1. PubMed ID: 17569830
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypothyroidism and muscular toxicity from fenofibrate, report of a case revealed by polymyositis].
    Cherif O; Karma F; Ben Amor G; Kochbati S; Ben Amor B; Rokbani L
    Tunis Med; 1997 Feb; 75(2):87-91. PubMed ID: 9506029
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver failure in a patient receiving rosiglitazone therapy.
    Su DH; Lai MY; Wu HP
    Diabet Med; 2006 Jan; 23(1):105-6. PubMed ID: 16409577
    [No Abstract]   [Full Text] [Related]  

  • 19. Gynecomastia associated with fenofibrate.
    Gardette V; Vezzosi D; Maiza JC; Montastruc JL; Olivier P
    Ann Pharmacother; 2007 Mar; 41(3):508-10. PubMed ID: 17341535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Muscular toxicity due to fenofibrate. Apropos of a case].
    Giraud P; Cassou M; Paul R; Guidet M
    Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):162. PubMed ID: 7063798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.